[Outcome of Preoperative Chemotherapy(FOLFOXIRI plus Bevacizumab)for Advanced Rectal Cancer]

We have administered FOLFOXIRI plus bevacizumab as preoperative chemotherapy for patients with advanced rectal cancer and have experienced difficulties in securing circumferential resection margins(CRMs)of 1 mm. This study included 13 patients with advanced rectal cancer who underwent surgery after receiving preoperative chemotherapy(FOLFOXIRI plus bevacizumab)at our hospital between January 2018 and July 2023. Eight patients(61.5%)had neutropenia of CTCAE Grade 3 or higher. The response rate to preoperative chemotherapy was 92.3%(SD in 1 patient, and PR in 12 patients), and pathological evaluation revealed pCR in 2 patients(15.3%). Postoperative recurrence of distant metastasis was observed in 2 patients(1 in the lung and 1 in the liver), both of whom underwent resection of the metastatic sites and are currently alive. Preoperative FOLFOXIRI plus bevacizumab therapy for advanced rectal cancer is considered a useful treatment for patients with advanced rectal cancer who have difficulty achieving a CRM of 1 mm.